Literature DB >> 24414246

[Practical guidelines for diagnosis and therapy of restless legs syndrome].

M Krenzer1, W Oertel, C Trenkwalder.   

Abstract

Restless legs syndrome (RLS) is the most common neurological sleep disorder affecting 10 % of the Caucasian population. The disorder is characterized by painful sensations in the lower limbs, especially during the evening, at night and during rest, resulting in an urge to move the legs and insomnia. As a result the quality of life is significantly reduced. Dopaminergic agents, opioids and anticonvulsants have proven to be effective for RLS with only the former being currently licensed; however, affected patients have to be identified, which is not always the case, especially in outpatient settings. Possible impediments to the adequate management of patients with RLS may include a lack of awareness, comorbidities and other medical conditions mimicking RLS. To overcome some of these difficulties practical guidelines for the diagnosis and therapy of RLS are provided.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24414246     DOI: 10.1007/s00115-013-3888-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  58 in total

1.  The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics").

Authors:  Wayne A Hening; Richard P Allen; Mystinna Washburn; Suzanne R Lesage; Christopher J Earley
Journal:  Sleep Med       Date:  2009-01-29       Impact factor: 3.492

2.  Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.

Authors:  Wayne A Hening; Richard P Allen; William G Ondo; Arthur S Walters; John W Winkelman; Philip Becker; Richard Bogan; June M Fry; David B Kudrow; Kurt W Lesh; Andreas Fichtner; Erwin Schollmayer
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

3.  Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

Authors:  Wolfgang Oertel; Claudia Trenkwalder; Heike Beneš; Luigi Ferini-Strambi; Birgit Högl; Werner Poewe; Karin Stiasny-Kolster; Andreas Fichtner; Erwin Schollmayer; Ralf Kohnen; Diego García-Borreguero
Journal:  Lancet Neurol       Date:  2011-06-24       Impact factor: 44.182

4.  Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.

Authors:  D Garcia-Borreguero; O Larrosa; Y de la Llave; K Verger; X Masramon; G Hernandez
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

5.  Idiopathic restless legs syndrome: abnormalities in central somatosensory processing.

Authors:  Jörn Schattschneider; Andre Bode; Gunnar Wasner; Andreas Binder; Günther Deuschl; Ralf Baron
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

6.  Hyperalgesia and functional sensory loss in restless legs syndrome.

Authors:  Karin Stiasny-Kolster; Doreen B Pfau; Wolfgang H Oertel; Rolf-Detlef Treede; Walter Magerl
Journal:  Pain       Date:  2013-05-10       Impact factor: 6.961

7.  Restless legs syndrome and pregnancy.

Authors:  M Manconi; V Govoni; A De Vito; N T Economou; E Cesnik; I Casetta; G Mollica; L Ferini-Strambi; E Granieri
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

8.  Iron and the restless legs syndrome.

Authors:  E R Sun; C A Chen; G Ho; C J Earley; R P Allen
Journal:  Sleep       Date:  1998-06-15       Impact factor: 5.849

Review 9.  State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome.

Authors:  Wolfgang H Oertel; Claudia Trenkwalder; Marco Zucconi; Heike Benes; Diego Garcia Borreguero; Claudio Bassetti; Markku Partinen; Luigi Ferini-Strambi; Karin Stiasny-Kolster
Journal:  Mov Disord       Date:  2007       Impact factor: 10.338

10.  The relationship between depressive symptoms and restless legs syndrome in two prospective cohort studies.

Authors:  Andras Szentkiralyi; Henry Völzke; Wolfgang Hoffmann; Bernhard T Baune; Klaus Berger
Journal:  Psychosom Med       Date:  2013-04-10       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.